JP2008531690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531690A5 JP2008531690A5 JP2007558085A JP2007558085A JP2008531690A5 JP 2008531690 A5 JP2008531690 A5 JP 2008531690A5 JP 2007558085 A JP2007558085 A JP 2007558085A JP 2007558085 A JP2007558085 A JP 2007558085A JP 2008531690 A5 JP2008531690 A5 JP 2008531690A5
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- alkyl
- methyl
- dimethylbut
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 85
- 150000001875 compounds Chemical class 0.000 claims 62
- 125000005843 halogen group Chemical group 0.000 claims 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- AVDFJTVPLPAJIW-GQCTYLIASA-N 2-methyl-n-(1h-pyrrolo[2,3-b]pyridin-5-yl)-4-[(e)-3,3,3-trifluoroprop-1-enyl]benzamide Chemical compound CC1=CC(\C=C\C(F)(F)F)=CC=C1C(=O)NC1=CN=C(NC=C2)C2=C1 AVDFJTVPLPAJIW-GQCTYLIASA-N 0.000 claims 1
- DBWSDTASIYVHGK-UHFFFAOYSA-N 4-(2-cyclopentylethynyl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCCOC3=CC=2)C(C)=CC=1C#CC1CCCC1 DBWSDTASIYVHGK-UHFFFAOYSA-N 0.000 claims 1
- OWOXOOQWUMVUJB-UHFFFAOYSA-N 4-(2-cyclopentylethynyl)-n-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCCNC3=CC=2)C(C)=CC=1C#CC1CCCC1 OWOXOOQWUMVUJB-UHFFFAOYSA-N 0.000 claims 1
- XTBIZNRIJZELOH-UHFFFAOYSA-N 4-(2-cyclopentylethynyl)-n-[2-(cyclopropylmethoxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC2CCCC2)=CC=C1C(=O)NC(C=C1OC2)=CC=C1OC2COCC1CC1 XTBIZNRIJZELOH-UHFFFAOYSA-N 0.000 claims 1
- FHDFQKHTVRNKMK-UHFFFAOYSA-N 4-(2-cyclopentylethynyl)-n-[2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCC(CO)OC3=CC=2)C(C)=CC=1C#CC1CCCC1 FHDFQKHTVRNKMK-UHFFFAOYSA-N 0.000 claims 1
- JMKYFKZCZVZTCG-UHFFFAOYSA-N 4-(2-cyclopentylethynyl)-n-[3-(hydroxymethyl)-3,4-dihydro-2h-1,4-benzoxazin-7-yl]-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCC(CO)NC3=CC=2)C(C)=CC=1C#CC1CCCC1 JMKYFKZCZVZTCG-UHFFFAOYSA-N 0.000 claims 1
- IDLGBOIZDMCNQL-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-fluorobenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCCOC3=CC=2)C(F)=CC=1C#CC1CC1 IDLGBOIZDMCNQL-UHFFFAOYSA-N 0.000 claims 1
- NIFGORPPVGCEDM-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCCOC3=CC=2)C(C)=CC=1C#CC1CC1 NIFGORPPVGCEDM-UHFFFAOYSA-N 0.000 claims 1
- COYGVXOKZNBLIH-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-2,6-difluorobenzamide Chemical compound C=1C(F)=C(C(=O)NC=2C=C3OCCNC3=CC=2)C(F)=CC=1C#CC1CC1 COYGVXOKZNBLIH-UHFFFAOYSA-N 0.000 claims 1
- RNXYNJBHGQCRQZ-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-2-fluorobenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCCNC3=CC=2)C(F)=CC=1C#CC1CC1 RNXYNJBHGQCRQZ-UHFFFAOYSA-N 0.000 claims 1
- LBWSFDOZKFREFZ-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCCNC3=CC=2)C(C)=CC=1C#CC1CC1 LBWSFDOZKFREFZ-UHFFFAOYSA-N 0.000 claims 1
- HCVVEIMNFNQOJI-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-[2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCC(CO)OC3=CC=2)C(C)=CC=1C#CC1CC1 HCVVEIMNFNQOJI-UHFFFAOYSA-N 0.000 claims 1
- AVMCWYQXLMOVMV-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-n-[3-(hydroxymethyl)-3,4-dihydro-2h-1,4-benzoxazin-7-yl]-2-methylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=C3OCC(CO)NC3=CC=2)C(C)=CC=1C#CC1CC1 AVMCWYQXLMOVMV-UHFFFAOYSA-N 0.000 claims 1
- JSFFCQYNKLMMBD-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-2-fluoro-n-isoquinolin-5-yl-3-methoxybenzamide Chemical compound C1=C(C#CC(C)(C)C)C(OC)=C(F)C(C(=O)NC=2C3=CC=NC=C3C=CC=2)=C1 JSFFCQYNKLMMBD-UHFFFAOYSA-N 0.000 claims 1
- YDCFCFVDKDKFIN-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-2-methyl-n-(1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CN=C(NC=C2)C2=C1 YDCFCFVDKDKFIN-UHFFFAOYSA-N 0.000 claims 1
- RMMNPRXBBOLYLM-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-(1,3-dioxoisoindol-5-yl)-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(C(=O)NC2=O)C2=C1 RMMNPRXBBOLYLM-UHFFFAOYSA-N 0.000 claims 1
- FFEXJOBIEUWQNB-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-(1h-indol-7-yl)-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=CC2=C1NC=C2 FFEXJOBIEUWQNB-UHFFFAOYSA-N 0.000 claims 1
- LCRHVNRNYJNLDF-GOSISDBHSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[(3r)-3-(hydroxymethyl)-3,4-dihydro-2h-1,4-benzoxazin-7-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(N[C@H](CO)CO2)C2=C1 LCRHVNRNYJNLDF-GOSISDBHSA-N 0.000 claims 1
- LCRHVNRNYJNLDF-SFHVURJKSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[(3s)-3-(hydroxymethyl)-3,4-dihydro-2h-1,4-benzoxazin-7-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(N[C@@H](CO)CO2)C2=C1 LCRHVNRNYJNLDF-SFHVURJKSA-N 0.000 claims 1
- ILUKVGXPSWCYOW-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(SC(CO)=N2)C2=C1 ILUKVGXPSWCYOW-UHFFFAOYSA-N 0.000 claims 1
- JMDBGOZPZLFFGI-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[2-(hydroxymethyl)-1h-imidazo[4,5-b]pyridin-6-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CN=C(NC(CO)=N2)C2=C1 JMDBGOZPZLFFGI-UHFFFAOYSA-N 0.000 claims 1
- BTVAUGAXRATXOO-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(OC(CO)CO2)C2=C1 BTVAUGAXRATXOO-UHFFFAOYSA-N 0.000 claims 1
- LCRHVNRNYJNLDF-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[3-(hydroxymethyl)-3,4-dihydro-2h-1,4-benzoxazin-7-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(NC(CO)CO2)C2=C1 LCRHVNRNYJNLDF-UHFFFAOYSA-N 0.000 claims 1
- PXGUMMMDQMJISS-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-[7-(hydroxymethyl)quinolin-3-yl]-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CN=C(C=C(CO)C=C2)C2=C1 PXGUMMMDQMJISS-UHFFFAOYSA-N 0.000 claims 1
- UEIJKWKBMGFJDH-UHFFFAOYSA-N 4-(3,3-dimethylbut-1-ynyl)-n-isoquinolin-5-yl-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=CC2=CN=CC=C12 UEIJKWKBMGFJDH-UHFFFAOYSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- DGVNBTPBUBMCSL-UHFFFAOYSA-N n-(1,3-benzothiazol-5-yl)-4-(3,3-dimethylbut-1-ynyl)-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(SC=N2)C2=C1 DGVNBTPBUBMCSL-UHFFFAOYSA-N 0.000 claims 1
- LWZKAZSVYHGKFY-UHFFFAOYSA-N n-(1-chloroisoquinolin-5-yl)-4-(3,3-dimethylbut-1-ynyl)-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=CC2=C(Cl)N=CC=C12 LWZKAZSVYHGKFY-UHFFFAOYSA-N 0.000 claims 1
- LHZASPWHPSOTAY-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3,3-dimethylbut-1-ynyl)-2-fluorobenzamide Chemical compound FC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(OCCO2)C2=C1 LHZASPWHPSOTAY-UHFFFAOYSA-N 0.000 claims 1
- SLDJNLXBGBUDBJ-UHFFFAOYSA-N n-(3,3,3-trifluoroprop-1-enyl)benzamide Chemical compound FC(F)(F)C=CNC(=O)C1=CC=CC=C1 SLDJNLXBGBUDBJ-UHFFFAOYSA-N 0.000 claims 1
- OVJKNJHLNIDFLH-UHFFFAOYSA-N n-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-4-(3,3-dimethylbut-1-ynyl)-2-fluorobenzamide Chemical compound FC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(NCCO2)C2=C1 OVJKNJHLNIDFLH-UHFFFAOYSA-N 0.000 claims 1
- RBLPCXVQMWNKBP-UHFFFAOYSA-N n-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-4-(3,3-dimethylbut-1-ynyl)-2-methoxybenzamide Chemical compound COC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(NCCO2)C2=C1 RBLPCXVQMWNKBP-UHFFFAOYSA-N 0.000 claims 1
- VYICSWRDBKRADJ-UHFFFAOYSA-N n-(3h-benzimidazol-5-yl)-4-(3,3-dimethylbut-1-ynyl)-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(NC=N2)C2=C1 VYICSWRDBKRADJ-UHFFFAOYSA-N 0.000 claims 1
- HEFKSJFIKZCQEP-UHFFFAOYSA-N n-[2-(cyclopropylmethoxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-4-(3,3-dimethylbut-1-ynyl)-2-methylbenzamide Chemical compound CC1=CC(C#CC(C)(C)C)=CC=C1C(=O)NC1=CC=C(OC(COCC2CC2)CO2)C2=C1 HEFKSJFIKZCQEP-UHFFFAOYSA-N 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65698405P | 2005-02-28 | 2005-02-28 | |
| US71044505P | 2005-08-23 | 2005-08-23 | |
| US77610506P | 2006-02-23 | 2006-02-23 | |
| US77610606P | 2006-02-23 | 2006-02-23 | |
| US77605706P | 2006-02-23 | 2006-02-23 | |
| US77606406P | 2006-02-23 | 2006-02-23 | |
| US77594506P | 2006-02-23 | 2006-02-23 | |
| US77594906P | 2006-02-23 | 2006-02-23 | |
| US77605606P | 2006-02-23 | 2006-02-23 | |
| US77593006P | 2006-02-23 | 2006-02-23 | |
| US77603306P | 2006-02-23 | 2006-02-23 | |
| US77605806P | 2006-02-23 | 2006-02-23 | |
| PCT/US2006/006615 WO2006093832A2 (en) | 2005-02-28 | 2006-02-24 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| US83999406P | 2006-08-24 | 2006-08-24 | |
| US83990306P | 2006-08-24 | 2006-08-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531690A JP2008531690A (ja) | 2008-08-14 |
| JP2008531690A5 true JP2008531690A5 (https=) | 2009-04-16 |
Family
ID=39773016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558085A Pending JP2008531690A (ja) | 2005-02-28 | 2006-02-24 | イオンチャネルリガンドとしてのアミド誘導体並びにそれを使用する医薬組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1853269A4 (https=) |
| JP (1) | JP2008531690A (https=) |
| KR (1) | KR20070119655A (https=) |
| AP (1) | AP2007004119A0 (https=) |
| AU (2) | AU2006218824A1 (https=) |
| CA (1) | CA2600933A1 (https=) |
| NO (1) | NO20074739L (https=) |
| WO (2) | WO2006093832A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008531690A (ja) * | 2005-02-28 | 2008-08-14 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体並びにそれを使用する医薬組成物及び方法 |
| US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| AU2008223348A1 (en) * | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| US8853392B2 (en) | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| SG185285A1 (en) * | 2007-06-03 | 2012-11-29 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| US8153651B2 (en) * | 2007-11-13 | 2012-04-10 | Evotec Ag | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| KR20100103799A (ko) * | 2007-11-16 | 2010-09-28 | 네우렉슨 인코포레이티드 | 내장통을 치료하기 위한 인돌 화합물 및 방법 |
| FR2933977B1 (fr) * | 2008-07-18 | 2013-04-26 | Centre Nat Rech Scient | Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives |
| WO2011016234A1 (en) * | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
| EP2707373A1 (de) | 2011-05-10 | 2014-03-19 | Bayer Intellectual Property GmbH | Bicyclische (thio)carbonylamidine |
| MY167697A (en) * | 2011-09-29 | 2018-09-21 | Mitsui Chemicals Agro Inc | Method for producing 4,4-difluoro-3,4- dihydroisoquinoline derivatives |
| US9193706B2 (en) | 2011-09-29 | 2015-11-24 | Mitsui Chemicals Agro, Inc. | Method for producing 3,4-dihydroisoquinoline derivatives and production intermediates of same |
| CA2854266A1 (en) | 2011-11-30 | 2013-06-06 | Actelion Pharmaceuticals Ltd | 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| WO2014113467A1 (en) * | 2013-01-15 | 2014-07-24 | Board Of Regents, The University Of Texas System | Stat3 inhibitor |
| WO2022200576A1 (en) * | 2021-03-26 | 2022-09-29 | Chiesi Farmaceutici S.P.A. | Indoline derivatives as ddr1 and ddr2 inhibitors |
| CN115353479A (zh) * | 2022-07-27 | 2022-11-18 | 常州琦诺生物科技有限公司 | 一种5-溴-2-碘嘧啶的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE144248T1 (de) * | 1992-07-01 | 1996-11-15 | Hoechst Ag | 3,4,5-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
| EP1023291B1 (en) * | 1997-10-07 | 2004-05-26 | Ortho-McNeil Pharmaceutical, Inc. | Dipyridoimidazolderivatives useful in treating central nervous system disorders |
| AR045979A1 (es) * | 2003-04-28 | 2005-11-23 | Astrazeneca Ab | Amidas heterociclicas |
| BRPI0415179A (pt) * | 2003-10-07 | 2006-11-28 | Renovis Inc | derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas |
| EP1775283A4 (en) * | 2004-07-14 | 2008-12-10 | Japan Tobacco Inc | 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1) |
| JP2008531690A (ja) * | 2005-02-28 | 2008-08-14 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体並びにそれを使用する医薬組成物及び方法 |
-
2006
- 2006-02-24 JP JP2007558085A patent/JP2008531690A/ja active Pending
- 2006-02-24 EP EP06736043A patent/EP1853269A4/en not_active Withdrawn
- 2006-02-24 KR KR1020077022045A patent/KR20070119655A/ko not_active Withdrawn
- 2006-02-24 WO PCT/US2006/006615 patent/WO2006093832A2/en not_active Ceased
- 2006-02-24 AP AP2007004119A patent/AP2007004119A0/xx unknown
- 2006-02-24 CA CA002600933A patent/CA2600933A1/en not_active Abandoned
- 2006-02-24 AU AU2006218824A patent/AU2006218824A1/en not_active Abandoned
-
2007
- 2007-02-22 WO PCT/US2007/004912 patent/WO2007100758A2/en not_active Ceased
- 2007-02-22 AU AU2007221118A patent/AU2007221118A1/en not_active Abandoned
- 2007-02-22 EP EP07751654A patent/EP1954132A4/en not_active Withdrawn
- 2007-09-17 NO NO20074739A patent/NO20074739L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531690A5 (https=) | ||
| US9133122B2 (en) | Amide compounds, compositions and uses thereof | |
| CN1131212C (zh) | 苯基－和吡啶基衍生物 | |
| US8946439B2 (en) | Amide compounds, compositions and uses thereof | |
| ES2585262T3 (es) | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 | |
| JP2009538358A (ja) | 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター | |
| CA2645257A1 (en) | Sulfonyl benzimidazole derivatives | |
| JP2009536918A5 (https=) | ||
| JP5552121B2 (ja) | ロイコトリエン産生のインドリジン阻害剤 | |
| HRP20110670T1 (hr) | Derivati 4-(2-amino-1-hidroksietil)fenola kao agonisti beta-2 adrenergičkog receptora | |
| RU2008100606A (ru) | Ингибиторы сфингозинкиназы | |
| JP2013538801A5 (https=) | ||
| JP2017533968A5 (https=) | ||
| JP2008508247A5 (https=) | ||
| JP2013519724A5 (https=) | ||
| JP2013510884A5 (https=) | ||
| US8785474B2 (en) | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | |
| CN108884044B (zh) | 哌啶衍生物 | |
| JP2010523727A5 (https=) | ||
| CA2610354A1 (en) | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists | |
| JP2017513825A5 (https=) | ||
| JP2010514734A5 (https=) | ||
| EP4565575A1 (en) | Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | |
| JP2020517676A5 (https=) | ||
| JP2008533154A5 (https=) |